# Biomarker Guided Treatment in DLBCL

> **NCT04025593** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 128 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Ibrutinib
- **DRUG:** Lenalidomide
- **DRUG:** chidamide
- **DRUG:** decitabine

## Key facts

- **NCT ID:** NCT04025593
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-17
- **Primary completion:** 2021-07-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04025593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04025593, "Biomarker Guided Treatment in DLBCL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04025593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*